N-(2-methyl-4-oxoquinazolin-3(4H)-yl)-3-oxoindoline-2-carboxamide | 1394357-29-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-(2-methyl-4-oxoquinazolin-3(4H)-yl)-3-oxoindoline-2-carboxamide
• 英文别名: N-(2-methyl-4-oxoquinazolin-3-yl)-3-oxo-1,2-dihydroindole-2-carboxamide
• CAS: 1394357-29-9
• 化学式: C₁₈H₁₄N₄O₃
• 分子量: 334.334
• InChiKey: VWLWDHASLRECGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  25
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  90.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  邻氨基苯甲酸 、 2-氯-N-(2-甲基-4-氧喹唑啉-3-基)乙酰胺 以 乙醇 为溶剂， 反应 1.5h， 以54%的产率得到N-(2-methyl-4-oxoquinazolin-3(4H)-yl)-3-oxoindoline-2-carboxamide
  参考文献：
  名称：

  Antitumor and antileishmanial evaluation of novel heterocycles derived from quinazoline scaffold: a molecular modeling approach

  摘要：

  Novel thiazole, pyrimidine and benzylidene derivatives derived from quinazoline scaffold have been synthesized. The antitumor evaluation of the newly synthesized products against three cancer cell lines namely breast adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460), and CNS cancer (SF-268) showed that the benzylidene-quinazoline derivative 12a showed remarkable activity against all three cell lines. The thiazolo-quinazoline derivative 10 showed greater activity than the control against breast adenocarcinoma (MCF-7) with a concentration of 0.01 mu M. Moreover, the antileishmanial activity of the newly synthesized products tested on Leishmania donovani amastigotes showed that compounds 4, 14, and 18 had very promising activity.

  DOI：

  10.1007/s00044-012-0213-9

文献信息

• Antitumor and antileishmanial evaluation of novel heterocycles derived from quinazoline scaffold: a molecular modeling approach
  作者：Daisy H. Fleita、Rafat M. Mohareb、Ola K. Sakka

  DOI：10.1007/s00044-012-0213-9

  日期：2013.5

  Novel thiazole, pyrimidine and benzylidene derivatives derived from quinazoline scaffold have been synthesized. The antitumor evaluation of the newly synthesized products against three cancer cell lines namely breast adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460), and CNS cancer (SF-268) showed that the benzylidene-quinazoline derivative 12a showed remarkable activity against all three cell lines. The thiazolo-quinazoline derivative 10 showed greater activity than the control against breast adenocarcinoma (MCF-7) with a concentration of 0.01 mu M. Moreover, the antileishmanial activity of the newly synthesized products tested on Leishmania donovani amastigotes showed that compounds 4, 14, and 18 had very promising activity.